Doubling Down on Mutant RAS Can MEK or Break Leukemia

Cell. 2017 Feb 23;168(5):749-750. doi: 10.1016/j.cell.2017.02.013.


Targeting of the RAS pathway has long been a critical therapeutic challenge in oncology. Burgess et al. examine how the relative expression of mutant and wild-type KRAS modulates clonal fitness and sensitivity to MEK inhibitors in a model of KrasG12D mutant acute myeloid leukemia and propose its use as a predictive biomarker.

MeSH terms

  • Genes, ras / drug effects
  • Humans
  • Leukemia, Myeloid, Acute
  • Mutation / drug effects*
  • Protein Kinase Inhibitors / pharmacology*
  • ras Proteins / genetics


  • Protein Kinase Inhibitors
  • ras Proteins